ENDRA Life Sciences To Pursue De Novo Pathway For TAEUS System
New path developed in consultation with the FDA to include limited confirmatory clinical data and provide potential future competitive advantages
ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc.
ENDRA Life Sciences Expands Into China With Shanghai General Hospital Partnership
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced it has received Institutional Review Board approval from China's renowned Shanghai General Hospital
ENDRA Life Sciences European Patent Register Doc For Co.’s ‘METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT’
https://register.epo.org/application?number=EP18842400
ENDRA Life Sciences Announces New Clinical Study Partnership With King’s College Hospital, London; Terms Not Disclosed
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that King's College Hospital, London (KCH) is now partnering with ENDRA for a clinical study of
ENDRA Life Sciences Expands Pharmaceutical Partnerships With VGI Health Technology To Provide TAEUS For Patient Screening And Biomarker Measurement For Phase 2 Study
ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), and VGI Health Technology Limited (NSX: VTL), a clinical-stage biotechnology company specializing in developing and
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Rani Therapeutics Hldgs (NASDAQ:RANI) stock rose 7.36% to $35.0 during Wednesday's after-market session. The company's market cap stands at $690.0 million. As per the news, the Q3 earnings report came out 2 days ago.
ENDRA Life Sciences Q3 EPS $(0.06) Beats $(0.07) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 60 percent increase over losses of $(0.15) per share from